


BIOGEN



PHARMACHEM INDUSTRIES LIMITED

CIN NO: L51100GJ1995PLC026702

(Formerly Known as SUN TECHNO OVERSEAS LIMITED)

13th August 2021.

To,
Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Dear Sir/Madam,

Sub: Un-Audited Financial Result quarter ending 30th June, 2021 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Un-audited financial results for quarter ended 30th June, 2021.

Kindly take the same on your record and oblige.

Thanking You,

Yours Faithfully,
For, **BIOGEN PHARMACHEM INDUSTRIES LIMITED**


DIRECTOR/AUTHORISED SIGNATORY

Biogen Pharmachem Industries Limited

(Formerly known as Sun Techno Overseas Limited)

CIN:- L65910GJ1995PLC026702

Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001

Email:- suntechnooverseas@gmail.com

Statement of Unaudited Financial Results for the Quarter Ended June 30, 2021

(Rs. In lacs)

Sl no.	Particulars	Quarter Ended 30 June 2021	Quarter Ended 31st March 2021	Quarter Ended 30 June 2020	Year Ended 31 Mar 2021
	(Refer Notes Below)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	REVENUE FROM OPERATIONS				
(a)	Income from Operations	125.15	162.26	-	162.26
(b)	Other Income	-	49.76	-	(160.81)
	Total Income	125.15	212.02	-	1.45
2	EXPENSES				
(a)	Cost of material consumed	98.24	148.06	-	148.06
(b)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-
(c)	Employee benefit expense	1.42	0.49	-	1.39
(d)	Finance Costs	-	-	-	-
(e)	Depreciation and Amortization Expense	-	-	-	-
(f)	Other expenses	5.40	1.54	0.15	12.32
	Total Expenses	105.06	150.09	0.15	161.77
3	Profit Before Exceptional items and tax	20.09	61.93	(0.15)	(160.32)
4	Exceptional Items	-	-	-	-
5	Profit / (Loss) before tax	20.09	61.93	(0.15)	(160.32)
6	Tax Expense	-	-	-	-
7	Net Profit for the period	20.09	61.93	(0.15)	(160.32)
8	Other comprehensive income	-	-	-	-
9	Total comprehensive income (9+10)	20.09	61.93	(0.15)	(160.32)
10	Paid-up equity share capital (Face Value of Rs.1/- each)	6,526.03	6,526.03	6,526.03	6,526.03
11	Other Equity				(1,111.75)
12	Earnings Per Share (of Rs. 1/- each):				
(a)	Basic	0.00	0.01	(0.00)	(0.02)
(b)	Diluted	0.00	0.01	(0.00)	(0.02)

Notes:

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 13, 2021. The Statutory Auditors have carried out a limited review of the above financial result.
- Company has only one segment and hence no separate segment result has been given.
- Pursuant to change of name of the company, there is requirement to show turnover from new activity separately. However, company is doing business only into new activity hence no separate turnover is shown for new activity.
- The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Place : Rajkot

Date : 13th August, 2021

By order of the Board

Director





RISHI SEKHRI AND ASSOCIATES

CHARTERED ACCOUNTANTS

GROUND FLOOR, BANDRA ARCADE BUILDING, OPP. RAILWAY STATION, BANDRA (WEST), MUMBAI - 400 050.
Tel.: 9820501848, 26419136, Email : rishisekhri@gmail.com

Limited Review Report

To
The Board of Directors of
BIOGEN PHARMACHEM INDUSTRIES LIMITED
RAJKOT

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **BIOGEN PHARMACHEM INDUSTRIES LIMITED**. ("the Company"), for the Quarter ended June 30th, 2021 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulation") as amended, read with Circular No. CIR/CFD/CMD1/80/2019 dated July 19th, 2019 ("the Circular").

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India, Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standard ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Rishi Sekhri and Associates
Chartered Accountants
FRN: 128216W

CA Rishi Sekhri
Partner
MEMBERSHIP NO. 126656

PLACE: MUMBAI
Date: 13/08/2021
UDIN: 21126656AADET9282

